MSVirtual2020: ACTRIMS-ECTRIMS | Physician's Weekly
Advertisement

MSVirtual2020: ACTRIMS-ECTRIMS

Functional potential of gut microbiome in paediatric MS

No overall differences in the functional diversity of the gut microbiome were found in patients with pediatric-onset MS in a study using metagenomic sequencing. However, there were differences in the functional potential...

Gold nanocrystals may improve brain metabolic profile

Interim results from two phase 2 studies provide evidence that orally delivered CNM-Au8 (gold nanocrystals) have catalytic effects on key bioenergetic metabolites in the brain of patients with MS and Parkinson’s disease...

Eculizumab reduces long-term relapse risk in AQP4+ NMOSD

Long-term efficacy and safety results of eculizumab monotherapy in patients with aquaporin-4 IgG-positive (AQP4+) neuromyelitis optica spectrum disorder (NMOSD) during the PREVENT trial and/or its ongoing open-label extension...

Predictive value of neurodegenerative CSF markers in MS

Cerebrospinal fluid (CSF) tau and beta-amyloid (Aβ) proteins are among the biomarkers currently applied in other neurodegenerative diseases than MS. Partly due to conflicting results, not a single biomarker of axonal damage in...

Management of PPMS and SPMS with approved DMT

In an invited lecture, Prof. Xavier Montalban (Vall d’Hebron University Hospital, Barcelona) discussed management of primary and secondary progressive MS (PPMS and SPMS) with approved disease-modifying treatment [1]....

Induction more effective than escalation as strategy in RRMS

An Italian study showed that long-term disability outcomes were more favourable with a strategy of early intensive treatment (EIT) than with moderate-efficacy treatment followed by escalation to higher-efficacy treatment (ESC)....

Low-dose rituximab as effective as high-dose, but safer

Results of a Spanish two-center study suggest that low doses of rituximab are equally effective as high doses, but have a superior safety profile. The anti-CD20 monoclonal antibody rituximab is not registered for the treatment...

Loading

Advertisement

For latest news and updates
Email-id is invalid